Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 10/20 | 0.64 |
| ▸ | PLG | P00747 | 9/20 | 0.64 |
| ▸ | F2 | P00734 | 8/20 | 0.64 |
| ▸ | F12 | P00748 | 6/20 | 0.64 |
| ▸ | KLK1 | P06870 | 3/20 | 0.64 |
| ▸ | C1R | P00736 | 2/20 | 0.64 |
| ▸ | F10 | P00742 | 2/20 | 0.64 |
| ▸ | HGFAC | Q04756 | 2/20 | 0.64 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.64 |
| ▸ | MLNR | O43193 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.64 |
| ▸ | HPN | P05981 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.64 |
| ▸ | C1S | P09871 | 1/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nafamostat SCHEMBL29429445 | 1.00 | PRSS1 (0.64) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL29429443 | 1.00 | PRSS1 (0.64) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL16069975 | 1.00 | PRSS1 (0.64) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL3302794 | 0.99 | PRSS1 (0.63) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL7345508 | 0.97 | PRSS1 (0.62) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL874941 | 0.94 | FTO (0.64) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL7051240 | 0.94 | PLAU (0.58) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL1568755 | 0.94 | FTO (0.70) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL564665 | 0.94 | FTO (0.70) | PRSS1PLGF2F12KLK1 | |
| Nafamostat SCHEMBL29832433 | 0.94 | FTO (0.70) | PRSS1PLGF2F12KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4150 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| US-12636253-B2 | Modified release compositions of nafamostat and methods of using same | Ensysce Biosciences Inc. (US) | 2026-05-26 | — | — | US | claimed |
| US-20260139035-A1 | HUMAN ANTIBODY AGAINST CORONAVIRUS VARIANTS OR ANTIGEN-BINDING FRAGMENT THEREOF | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2026-05-21 | — | — | US | claimed |
| US-20260130921-A1 | TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS | AcuraStem Incorporated (US) | 2026-05-14 | — | — | US | claimed |
| EP-4725496-A2 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NantCell, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12599578-B2 | Compositions comprising enzyme-cleavable prodrugs and controlled release nafamostat and methods of use thereof | Ensysce Biosciences Inc. (US) | 2026-04-14 | — | — | US | claimed |
| US-12599644-B2 | Treatment of coronavirus infection with Flt3 receptor interacting lectin (FRIL) | ACADEMIA SINICA (TW) | 2026-04-14 | — | — | US | claimed |
| US-20260007597-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRUS-INDUCED AIRWAY FIBROSIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2026-01-08 | — | — | US | claimed |
| US-20250345458-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250332247-A1 | IMPROVED CORONAVIRUS VACCINE | ACADEMIA SINICA (TW) | 2025-10-30 | — | — | US | claimed |
| EP-0647398-B1 | ORGAN PRESERVING FLUID | TORII PHARMACEUTICAL CO LTD (JP) | 1997-09-17 | — | — | EP | claimed |
| US-5565317-A | BIOLOGICAL ORGAN PRESERVATIVE; STORAGE STABILITY | TORII PHARMACEUTICAL CO., LTD. (JP) | 1996-10-15 | — | — | US | claimed |
| EP-0647398-A1 | ORGAN PRESERVING FLUID | TORII PHARMACEUTICAL CO., LTD (JP) | 1995-04-12 | — | — | EP | claimed |
| EP-0287036-B1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING ESTERS OR AMIDES AS ACTIVE INGREDIENTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 1991-04-10 | — | — | EP | claimed |
| US-4990537-A | 6-amidinonaphth-2-yl or p-(n,n-dimethylcarbamoyl methoxy-carbonyl methyl) phenyl ester of p-guanidinobenzoic acid | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-02-05 | — | — | US | claimed |
| EP-0350840-A2 | Antiviral agent | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-01-17 | — | — | EP | claimed |
| EP-0287036-A2 | New pharmaceutical compositions comprising esters or amides as active ingredients | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-10-19 | — | — | EP | claimed |
| EP-0048433-B1 | NOVEL AMIDINE COMPOUNDS, PROCESS FOR PRODUCING SAME AND ANTI-COMPLEMENT AGENT COMPRISING THEM | TORII & CO., LTD. (JP) | 1986-05-28 | — | — | EP | claimed |
| US-4454338-A | 6-AMIDINO-2-NATHTHYL-4-GUANIDINOBENZOATE | TORII & CO., LTD. (JP) | 1984-06-12 | — | — | US | claimed |
| EP-0048433-A2 | Novel amidine compounds, process for producing same and anti-complement agent comprising them | TORII & CO., LTD. (JP) | 1982-03-31 | — | — | EP | claimed |